Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers.
about
Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
P2860
Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Expression of pEGFR and pAKT a ...... metastatic colorectal cancers.
@ast
Expression of pEGFR and pAKT a ...... metastatic colorectal cancers.
@en
type
label
Expression of pEGFR and pAKT a ...... metastatic colorectal cancers.
@ast
Expression of pEGFR and pAKT a ...... metastatic colorectal cancers.
@en
prefLabel
Expression of pEGFR and pAKT a ...... metastatic colorectal cancers.
@ast
Expression of pEGFR and pAKT a ...... metastatic colorectal cancers.
@en
P2093
P2860
P50
P356
P1476
Expression of pEGFR and pAKT a ...... metastatic colorectal cancers.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2015.250
P407
P577
2015-07-14T00:00:00Z
P6179
1000646709